Home > Press > Nanogen Strengthens Cardiac Biomarker Patent Position as US Patent Office Reissues Patent for Diagnosis of Chronic Congestive Heart Failure
Nanogen, Inc. (NASDAQ:NGEN), developer of advanced diagnostic products, announced today that it has been granted U.S. Patent No. RE39,816, which is a reissue of United States Patent No. 6,461,828, titled, "Conjunctive Analysis of Biological Marker Expression For Predicting Cardiac Mortality". This patent relates to the combined use of a cardiac marker of cell injury, such as Troponin I, with a marker of organ adaptation, such as brain natriuretic peptide (BNP), for prognosis of chronic congestive heart failure (CHF) patients. The new claims strengthen the Company's intellectual property rights around the combined use of these two types of important biomarkers.
Nanogen Strengthens Cardiac Biomarker Patent Position as US Patent Office Reissues Patent for Diagnosis of Chronic Congestive Heart Failure
SAN DIEGO, CA | Posted on November 19th, 2007
"The combined use of Troponin I and BNP to evaluate the progress of congestive heart failure is just one example of how physicians currently combine biomarkers in cardiac care," said Howard Birndorf, CEO of Nanogen. "Reaffirmation of our IP position strengthens our cardiac related patent portfolio and positions us to market leadership point of care products that meet current clinical needs."
The Company currently has rapid diagnostic testing products in the market that test for cardiac markers separately. The company offers the Cardiac STATus® Troponin I rapid test product line acquired in 2006 and earlier this year announced the commercial release of its StatusFirst® CHF rapid test which uses the NT-proBNP marker. In addition, Nanogen holds key intellectual property rights around the use of multiple markers in a combined diagnostic test device with its 3-in-1 patent.
About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The Company’s products include real-time PCR reagents and kits based on the Company’s proprietary probe technology branded as MGB Alert® and Q-PCR Alert, and a line of rapid point-of-care diagnostic tests used in urgent care settings to aid in the diagnosis of heart failure conditions. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen’s website at http://www.nanogen.com .
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether restructuring of the array business would reduce operating cost and improve financial performance, whether acquisitions of other businesses would result in revenue growth in the real-time PCR and point-of-care testing market, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Kelly Goodwin Gann, Marketing Communications
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Zenosense, Inc. July 29th, 2014
Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014
President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014
Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014
Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014
Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014
UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014
Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014
Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014